References on Cancer Research Using ALZET^® Osmotic Pumps

P8437 Henke,E., Perk,J., Vider,J., de Candia,P., Chin,Y., Solit,D.B., Ponomarev,V., Cartegni,L., Manova,K., Rosen,N., Benezra,R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. NATURE BIOTECHNOLOGY 2008; 26(-1-):91-100. >>> Oligonucleotide, antisense, peptide conjugated; oligonucleotide, phosphorothioate antisense; peptide, F3; TBS; SC; Mice (nude); mice; 1007D; 1002; 14, 21 days; Controls received mp w/ vehicle or control peptide and oligo in non-conjugated form, or rcId1-PCAO; comparison of IV injections vs. mp; pumps replaced after 14 days; no stress (see pg. 95, 97); stability verified after 24 hours in 37 C, plasma up to 28 days in 37 C saline; antisense (Id1, rcId1); cancer (breast, lung carcinoma); peptides; toxicology; animal info (female, nude NCR; male, C57J/B6); antisense oligos covalently coupled to address peptide that targets tumor endothelial cells; "no adverse effects on treated mice have been observed." (p. 97).

R0243 Sachdev,D., Yee,D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. MOLECULAR CANCER THERAPEUTICS 2007; 6(-1-):1-12. >>> Insulin-like growth factor binding protein-1, recomb. human; BSA; SC; Mice; 2 weeks; Controls received mp w/ vehicle; comparison of SC injections vs. mp; half-life (p. 4) "very short;" cancer (breast); peptides; animal info (athymic); review, see pg. 4-5; "IGFBP-1 had to be administered via osmotic pumps because of its very short half-life and it was ineffective on a twice-daily schedule in vivo." (p. 4).

P8565 Veiseh,M., Gabikian,P., Bahrami,S.B., Veiseh,O., Zhang,M., Hackman,R.C., Ravanpay,A.C., Stroud,M.R., Kusuma,Y., Hansen,S.J., Kwok,D., Munoz,N.M., Sze,R.W., Grady,W.M., Greenberg,N.M., Ellenbogen,R.G., Olson,J.M. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 2007/7/15; 67(-14-):6882-6888. >>> Chlorotoxin; SC; Mice; ; Controls received mp w/ vehicle; cancer; peptides; scorpion venom (toxin).

P8564 van der Bilt,J.D.W., Soeters,M.E., Duyverman,A.M.M.J., Nijkamp,M.W., Witteveen,P.O., van Diest,P.J., Kranenburg,O., Rinkes,I.H.M.B. Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. American Journal of Pathology 2007; 170(-4-):1379-1388. >>> Arginine, L-; SC; Mice; 2001; 5 days; Controls received mp w/ vehicle; cancer (colorectal); animal info (male, BALB/c, 10-12 weeks old); nitric oxide donor.

P8542 Sakai,T., Balasubramanian,K., Maiti,S., Haider,J.B., Schroit,A.J. Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. American Journal of Pathology 2007; 171(-5-):1659-1669. >>> Glycoprotein 1, B-2-; glycoprotein 1, nicked B-2-; SC; IP; Mice; 2002; 28 days; Controls received mp w/ HSA; cancer (prostate adenocarcinoma); peptides; multiple pumps per animal (2); animal info (male, C57BL/6, 6 weeks old); B2GP1 is also known as apolipoprotein H; mp implanted IP on day 1, SC on day 14, implanted pumps not removed.

P8528 Neal,Z.C., Sondel,P.M., Bates,M.K., Gillies,S.D., Herweijer,H. Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory. CANCER IMMUNOLOGY IMMUNOTHERAPY 2007; 56(-11-):1765-1774. >>> Interleukin-2, recomb. human; SC; Mice; 2001; 4 days; Controls received mp w/ no treatment; cancer (neuroblastoma); peptides; animal info (female, A/J, ICR, 6-8 weeks old).

P8520 Kumar,R., Knick,V.B., Rudolph,S.K., Johnson,J.H., Crosby,R.M., Crouthamel,M.C., Hopper,T.M., Miller,C.G., Harrington,L.E., Onori,J.A., Mullin,R.J., Gilmer,T.M., Truesdale,A.T., Epperly,A.H., Boloor,A., Stafford,J.A., Luttrell,D.K., Cheung,M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. MOLECULAR CANCER THERAPEUTICS 2007; 6(-7-):2012-2021. >>> GW771806; SC; Mice (nude); mice (SCID); 2001; 5,6,21 days; Controls received mp w/ vehicle; dose-response (fig. 4); comparison of oral gavage vs. mp; cancer (colon); animal info (female, Swiss nu/nu, 8-12 weeks old); VEGFR inhibitor; "Continuous infusion of VEGFR inhibitor is more effective in controlling tumor growth and angiogenesis than p.o bolus dosing." (p. 2018).

P8514 Ishikawa,M., Kitayama,J., Yamauchi,T., Kadowaki,T., Maki,T., Miyato,H., Yamashita,H., Nagawa,H. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. CANCER SCIENCE 2007; 98(-7-):1120-1127. >>> Adiponectin, recomb. mouse; PBS; IP; Mice (nude); 2004; 14 days; Controls received mp w/ vehicle; comparison of intratumoral injections vs. mp; no stress (see pg. 1124); cancer (gastric); peptides; animal info (female, BALB/c, nude, 5 weeks old); "Continuous adiponectin infusion into the peritoneal cavity caused significant antitumor effects." (p. 1126); "The intraperitoneal infusion did not cause apparent side effects with no significant change of total weight." (p. 1124).

P8512 Huang,Y., Chen,X., Dikov,M.M., Novitskiy,S.V., Mosse,C.A., Yang,L., Carbone,D.P. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110(-2-):624-. >>> Vascular endothelial growth factor 165, recomb. human; vascular endothelial growth factor, receptor-2 selective; vascular endothelial growth factor, receptor-1 selective; Mice; 2004; 28 days; Controls received mp w/ PBS; cancer; peptides; animal info (female, Balb/c, 6-8 weeks old); angiogenesis; hematology.

P8510 Djalilian,H.R., Caicedo,E., Lessan,K., Grami,V., Le,C.T., Spellman,S.R., Pambuccian,S., Hall,W.A., Low,W.C., Ondrey,F.G. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats. CANCER IMMUNOLOGY IMMUNOTHERAPY 2007; 56(-8-):1207-1214. >>> Granulocyte macrophage-colony stimulating factor, murine; interleukin-12; PBS; SC; Rat; 28 days; Controls received mp w/ vehicle; dose-response (fig 1); no stress (see pg. 1209); cancer (upper aerodigestive tract carcinoma); peptides; animal info (Fisher 344, 125-150 g); good methods; "This latter method (mp) has several advantages. First, the use of minipumps obviates the cumbersome need to transfect tumor cells and completely characterize their cytokine repertoires. Second, it allows for independent and rigorous control over the kinetics of administration of cytokine and antigen dosages. Third, it may generate les controversy than those techniques requiring "gene therapy" IRB approval." (p. 1213)..

P8504 Wilkinson,R.W., Odedra,R., Heaton,S.P., Wedge,S.R., Keen,N.J., Crafter,C., Foster,J.R., Brady,M.C., Bigley,A., Brown,E., Byth,K.F., Barrass,N.C., Mundt,K.E., Foote,K.M., Heron,N.M., Jung,F.H., Mortlock,A.A., Boyle,F.T., Green,S. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clinical Cancer Research 2007; 13(-12-):3682-3688. >>> AZD1152; SC; Mice; 2001D; 48 hours; Controls received mp w/ vehicle; dose-response (p. 3684); comparison of IV or IP injections; enzyme inhibitor (aurora B kinase); cancer; xenograft; animal info (male, 8-12 weeks old, Swiss athymic).

P8498 Tsutsumi,H., Tanaka,T., Ohashi,N., Masuno,H., Tamamura,H., Hiramatsu,K., Araki,T., Ueda,S., Oishi,S., Fujii,N. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers (peptide Science) 2007; 88(-2-):279-289. >>> TN14003, 4F-benzoyl; SC; Mice; ; Cancer.

P8493 Thomas,E.K., Cancelas,J.A., Chae,H.D., Cox,A.D., Keller,P.J., Perrotti,D., Neviani,P., Druker,B.J., Setchell,K.D.R., Zheng,Y., Harris,C.E., Williams,D.A. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. CANCER CELL 2007; 12(-5-):467-478. >>> NSC23766; SC; Mice (SCID); 2002; 17 days; Cancer (leukemia).

P8489 Song,P., Sekhon,H.S., Lu,A., Arredondo,J., Sauer,D., Gravett,C., Mark,G.P., Grando,S.A., Spindel,E.R. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Research 2007; 67(-8-):3936-3944. >>> Dacifenacin; DMSO; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; plasma levels taken; dose-response (p. 3941); cancer (lung); tumors implanted in right flank; M3 receptor antagonist; xenograft; animal info (6-7 weeks old).

P8467 Zhang,Y.M., Bressler,J.P., Neal,J., Lal,B., Bhang,H.E.C., Laterra,J., Pomper,M.G. ABCG2/BCRP expression modulates D-luciferin-based bioluminescence imaging. Cancer Research 2007; 67(-19-):9389-9397. >>> Luciferin; SC; Mice (nude); 1007D; 1 hour; Cancer; bioluminescence imaging (BLI); animal info (female, nude); tumor cells injected SC; pg 939s shows images with pumps implanted.

P8463 Shen,X.Z., Li,P., Weiss,D., Fuchs,S., Xiao,H.D., Adams,J.A., Williams,I.R., Capecchi,M.R., Taylor,W.R., Bernstein,K.E. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. American Journal of Pathology 2007; 170(-6-):2122-2134. >>> Captopril; losartan; SC; Mice; 2 weeks; Functionality of mp verified by systolic blood pressure; enzyme inhibitor (ACE); cancer (melanoma); immunology; animal info (C56BL/6, wt, ACE 10/10, 8wks old).

P8456 Garbaccio,R.M., Tasbera,E.S., Neilson,L.A., Coleman,P.J., Fraley,M.E., Olson,C., Bergman,J., Torrent,M., Buser,C.A., Rickert,K., Walsh,E.S., Hamilton,K., Lobell,R.B., Tao,W.K., South,V.J., Diehl,R.E., Davide,J.P., Yan,Y.W., Kuo,L.C., Li,C.Z., Prueksaritanont,T., Fernandez-Metzler,C., Mahan,E.A., Slaughter,D.E., Salata,J.J., Kohl,N.E., Huber,H.E., Hartman,G.D. Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. BIOORGANIC&MEDICINAL CHEMISTRY LETTERS 2007; 17(-20-):5671-5676. >>> Kinesin spindle protein inhibitor; SC; Mice (nude); 2001D; 22-24 hours; Cancer (ovarian carcinoma); animal info (athymic nude).

P8443 Banach-Petrosky,W., Jessen,W.J., Ouyang,X., Gao,H., Rao,J., Quinn,J., Aronow,B.J., bate-Shen,C. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Research 2007; 67(-19-):9089-9096. >>> Testosterone propionate; PEG 400; SC; Mice; 2004; 7 months; Controls received mp w/ vehicle, or no treatment; replacement therapy (castration); dose-response (fig 1A); long-term study; pumps replaced every 28 days; cancer prostate; animal info (male, C57Bl/65X129/SvImJ, 6 wks old).

P8436 Rabbani,Z.N., Batinic-Haberle,I., Anscher,M.S., Huang,J., Day,B.J., Alexander,E., Dewhirst,M.W., Vujaskovic,Z. Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2007; 67(-2-):573-580. >>> AEOL 10150; SC; Rat; 2002; 10 weeks; 8 days; Controls received mp w/ vehicle; functionality of mp verified by plasma AEOL 10150 concentrations; dose-response (fig. 4); long-term study; pumps replaced every 2 weeks; half-life (p. 574), short; cancer; animal info (female, Fisher-344, 150-170 grams); "Osmotic mini-pumps provided consistent and dose-dependent delivery of AEOL 10150," "a continuous availability of antioxidant via osmotic infusion pumps throughout the study." (p. 575).

P8393 Yao,W.Q., Zhuo,J.C., Burns,D.M., Xu,M.Z., Zhang,C.L., Li,Y.L., Qian,D.Q., He,C.H., Weng,L.K., Shi,E., Lin,Q.Y., Agrios,C., Burn,T.C., Caulder,E., Covington,M.B., Fridman,J.S., Friedman,S., Katiyar,K., Hollis,G., Li,Y.L., Liu,C.N., Liu,X.D., Marando,C.A., Newton,R., Pan,M., Scherle,P., Taylor,N., Vaddi,K., Wasserman,Z.R., Wynn,R., Yeleswaram,S., Jalluri,R., Bower,M., Zhou,B.B., Metcalf,B. Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer. Journal of Medicinal Chemistry 2007; 50(-4-):603-606. >>> INCB3619; trastuzumab; SC; Mice; 28 days; Controls received mp w/ vehicle; enzyme inhibitor (HER-2 sheddase); cancer (breast); animal info (BT-474-SC1); trastuzumab is a humanized anti-HER-2 monoclonal antibody.

P8366 Dorrell,M.I., Aguilar,E., Scheppke,L., Barnett,F.H., Friedlander,M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-3-):967-972. >>> Vascular endothelial growth factor, aptamer; EMD472523; T2-TrpRS; PBS; CSF/CNS (intratumoral); Rat; 2001D; 2ML2; 2ML4; 3,6 days; 24 hours; Controls received mp w/ vehicle; cancer (gliosarcoma); animal info (male, Fischer, 344); EMD472523 is an integrin antagonist, VEGF aptamer is chemically identical to Macugen; T2 is a proteolytic fragment of tryptophan tRNA synthetase; all agents have angiostatic activity; tissue perfusion (tumor).

P8357 Mulder,W.J.M., van der Schaft,D.W.J., Hautvast,P.A.I., Strijkers,G.J., Koning,G.A., Storm,G., Mayo,K.H., Griffioen,A.W., Nicolay,K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB Journal 2007; 21(-2-):378-383. >>> Endostatin; anginex; SC; Mice; 2 weeks; 3 days; Controls received mp w/ saline; cancer (melanoma); peptides; MRI; animal info (C57BL/6, 6 weeks old); antiangiogenesis.

P8331 Joppa,M.A., Gogas,K.R., Foster,A.C., Markison,S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 2007; 28(-3-):636-642. >>> Agouti-related peptide (83-132); Saline, sterile; CSF/CNS; Mice; 1003D; 72 hours; Controls received mp w/ vehicle; cancer (colon adenocarcinoma); peptides; animal info (male, BALB/C, 6 weeks old, 22 grams).

P8330 Raafat,A., Zoltan-Jones,A., Strizzi,L., Bargo,S., Kimura,K., Salomon,D., Callahan,R. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis. ONCOGENE 2007; 26(-5-):662-672. >>> Imatinib mesylate; SC; Mice (transgenic); 2001; 1,3,4,5,7 days; Controls received mp w/ water; dose-response (fig 2); no stress (see pg. 663); cancer (mammary); animal info (female, FVB/N, 10 wks old); antiangiogenic; "Continuous release of Gleevec for a week resulted in 33% inhibition of tumor growth by day 2 and 66% by day 4." (p. 668).

P8323 Shibata,M.A., Morimoto,J., Doi,H., Morishima,S., Naka,M., Otsuki,Y. Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis. Cancer Gene Therapy 2007; 14(-3-):268-278. >>> Ganciclovir; Saline; SC; Mice; 2002; 8 weeks; Controls received mp w/ agent and empty control vector; long-term study; pumps replaced every 14 days; no stress (see pg. 271); cancer (mammary adenocarcinoma); animal info (BALB/C, female, 20-24 grams).

P8308 Price,R.J., Walters,D.G., Finch,J.M., Gabriel,K.L., Capen,C.C., Osimitz,T.G., Lake,B.G. A mode of action for induction of liver tumors by Pyrethrins in the rat. TOXICOLOGY AND APPLIED PHARMACOLOGY 2007; 218(-2-):186-195. >>> Uridine, bromodeoxy; Rat; 2ML1; 7 days; Cancer (liver); toxicology; animal info (male, female, Sprague-Dawley CD, 10-11 wks old); labeling of hepatocytes.

P8305 Mook,O.R., Baas,F., de Wissel,M.B., Fluiter,K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. MOLECULAR CANCER THERAPEUTICS 2007; 6(-3-):833-843. >>> RNA, small interfering; RNA, small interfering, LNA-modified; Radio-isotopes, 3H-; SC; Mice (nude); 1007D; 7 days; 48 hours; Controls received mp w/ mismatch siRNA or saline; comparison of IV injections vs. mp; stability verified by incubation in mouse serum; half-life (p. 837) increased in LNA-modified; unmodified completely degraded in<5 hours; cancer (pancreatic); animal info (NMRI nu/nu, 8-10 weeks old); siRNA against RNA polymerase II, enhanced GFP, or mismatch.

P8302 Zhang,X.F., Connolly,C., Duquette,M., Lawler,J., Parangi,S. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Letters 2007; 247(-1-):143-149. >>> Thrombospondin-1, three type 1 repeats; PBS; SC; Mice (SCID); 1007D; 7 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; stability verified by incubation in pump, 7 days; cancer (pancreatic); peptides; animal info (female, SCID, 4-6 weeks old); antiangiogenesis therapy; 3TSR; "Continuous administration of 3TSR reduced dosage and improved therapeutic potency." p. 146.

P8301 Badn,W., Hegardt,P., Fellert,M.A., Darabi,A., Esbjoernsson,M., Smith,K.E., Janelidze,S., Salford,L.G., Visse,E., Siesjoe,P. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. SCANDINAVIAN JOURNAL OF IMMUNOLOGY 2007; 65(-3-):289-297. >>> L-NAME; L-NIL; Saline; IP; Rat; 2001; 1 week; 14, 28 days; Controls received mp w/ vehicle; dose-response (fig. 3); comparison of IP injections vs. mp; enzyme inhibitor (Nitric oxide synthase, iNOS); cancer (glioma); L-NIL is L-N6- (1-iminsethyl) -L-lysine.

P8293 Suzuki,E., Kim,S., Cheung,H.K., Corbley,M.J., Zhang,X.M., Sun,L.H., Shan,F., Singh,J., Lee,W.C., Albelda,S.M., Ling,L.E. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Research 2007; 67(-5-):2351-2359. >>> SM16; Captisol; SC; Mice; 2004; 10 days; Controls received mp w/ vehicle; SM16 plasma levels taken; dose-response (p. 2354); enzyme inhibitor (ALK5 kinase); cancer (mesothelioma); animal info (Balb/c, 6-8 weeks old, 19-24 grams); "This mode of delivery [pumps] maintains consistent plasma levels of SM16 over the course of the study." p. 2356.

P8285 Yang,L.H., Jackson,E., Woerner,B.M., Perry,A., Piwnica-Worms,D., Rubin,J.B. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Research 2007; 67(-2-):651-658. >>> AMD3465; PBS; SC; Mice; ; Controls received mp w/ vehicle; cancer (brain); BLI, IVIS imaging performed; 0.25 ul/hr pump used.

P8276 Rustamzadeh,E., Hall,W.A., Todhunter,D.A., Vallera,V.D., Low,W.C., Liu,H.Y., Panoskaltsis-Mortari,A., Vallera,D.A. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. International Journal of Cancer 2007; 120(-2-):411-419. >>> DTAT; Saline; CSF/CNS; Mice; 1007D; ; Controls received mp w/ vehicle; dose-response (table 1); comparison of bolus ICV injections vs. mp; cancer (glioblastoma); toxicology; peptides; animal info (C57BL/6, female, 12 weeks old); diptheria toxin; "delivery of DTAT resulted in about a 16 fold increase in maximum tolerated dose." (p. 411); "The results of this experiment indicate that the toxicity of uPAR can be reduced by CED (mp) delivery." (p. 416).

P8226 Michaud-Levesque,J., Demeule,M., Beliveau,R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. Carcinogenesis 2007; 28(-2-):280-288. >>> Melanotransferrin, soluble, truncated recomb. human; melanotransferrin, [125I]-soluble, truncated recomb. human; Ringers's solution; HEPES solution; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; dose-response (fig. 6); comparison of SC injections vs. mp; half-life (p. 285) ~7.6 hours + or - 0.9 hours; cancer; peptides; animal info (female, athymic CD-1-nuBr, 5-10 weeks old); "The use of ALZET osmotic pump infusion technique provided a higher therapeutic efficacy as compared with repeated S.C. injections, emphasizing the advantages of constant infusion rather than pulse-dose drug inputs for antiangiogenic effects." (p. 287).

P8224 Menon,J., Soto-Pantoja,D.R., Callahan,M.F., Cline,J.M., Ferrario,C.M., Tallant,E.A., Gallagher,P.E. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Research 2007; 67(-6-):2809-2815. >>> Angiotensin (1-7); Saline; heparin; IV (jugular); Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; no stress (see pg. 2810); cancer (lung); peptides; animal info (male, athymic, 2-4 weeks old, 15-20 grams); "During the infusion period, the animals maintained their body weight as well as food and water consumption and showed no evidence of reduced motor function. Additionally, no gross pathological abnormalities were observed in major organs..indicating a lack of toxic side effects." (p. 2810).

P8203 Masunaga,S., Nagasawa,H., Nagata,K., Suzuki,M., Uto,Y., Hori,H., Kinashi,Y., Ono,K. Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells. Journal of Cancer Research and Clinical Oncology 2007; 133(-1-):47-55. >>> Uridine, bromodeoxy; Saline, physiological; SC; Mice; 5, 8 days; Cancer (carcinoma); animal info (female, 8-11 wks old).

P8110 Iwasaki,Y., Ueda,M., Yamada,T., Kondo,A., Seno,M., Tanizawa,K., Kuroda,S., Sakamoto,M., Kitajima,M. Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Therapy 2007; 14(-1-):74-81. >>> Ganciclovir; Water, sterile; SC; Rat (nude); 12 days; Controls received mp w/ agent and plasmid w/out gene therapy gene; no stress (see p.78); cancer (liver); gene therapy; animal info (male, F344/N, nu/nu, 5 wks old, 180g., NuE hepatic tumors); GCV acts as pro-drug for HSV-tk expression plasmid gene therapy.

P8016 Fridman,J.S., Caulder,E., Hansbury,M., Liu,X.D., Yang,G.J., Wang,Q., Lo,Y., Zhou,B.B., Pan,M., Thomas,S.M., Grandis,J.R., Zhuo,J.C., Yao,W.Q., Newton,R.C., Friedman,S.M., Scherle,P.A., Vaddi,K. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research 2007; 13(-6-):1892-1902. >>> Marimastat; INCB3619; SC; Mice; mice (nude); 7, 14 days; Controls received mp w/ vehicle; enzyme inhibitor (metalloprotease); cancer (squamous cell carcinoma, breast, lung carcinoma); toxicology; animal info (BALB/c, CD-1 nu/nu); ErbB ligand shedding inhibitor.

P7964 Mortlock,A.A., Foote,K.M., Heron,N.M., Jung,F.H., Pasquet,G., Lohmann,J.J., Warin,N., Renaud,F., Savi,C.D., Roberts,N.J., Johnson,T., Dousson,C.B., Hill,G.B., Perkins,D., Hatter,G., Wilkinson,R.W., Wedge,S.R., Heaton,S.P., Odedra,R., Keen,N.J., Crafter,C., Brown,E., Thompson,K., Brightwell,S., Khatri,L., Brady,M.C., Kearney,S., McKillop,D., Rhead,S., Parry,T., Green,S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J.Med.Chem. 2007/3/21; Online only(--):-. >>> AZD1152; Tris buffer; SC; Mice; 2001D; 48 hours; Enzyme inhibitor (aurora kinase); cancer; animal info (male, Swiss, nu/nu); PK data; xenograft; tumor cells on dorsal flank.

R0238 Boeckle,S., Wagner,E. Optimizing targeted gene delivery: Chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS Journal 2006; 8(-4-):E731-E742. >>> Virus, synthetic RNA; Intratumoral; Mice (nude); ; Cancer (glioblastoma); "Control animals within 30 days after tumor implantation, all treated animals survived for >1 year and were completely cured." (p. E738).

P8332 Prevost,G.P., Lonchampt,M.O., Holbeck,S., Attoub,S., Zaharevitz,D., Alley,M., Wright,J., Brezak,M.C., Coulomb,H., Savola,A., Huchet,M., Chaumeron,S., Nguyen,Q.D., Forgez,P., Bruyneel,E., Bracke,M., Ferrandis,E., Roubert,P., Demarquay,D., Gespach,C., Kasprzyk,P.G. Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric G alpha /G beta gamma protein complex. Cancer Research 2006; 66(-18-):9227-9234. >>> BIM-46174; Rat; 6 days; No stress (see pg. 9231); cancer (lung); toxicology.

P8295 Uesato,N., Fukui,K., Maruhashi,J., Tojo,A., Tajima,N. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model. Experimental Hematology 2006; 34(-10-):1385-1392. >>> JTE-607; Cyclodextrin, 2-hydroxypropyl-beta; SC; Mice (SCID); 2001; 7 days; Controls received mp w/ vehicle; comparison of bolus injections vs. mp; cancer (leukemia); animal info (8-9 weeks old); xenograft; multiple cytokine inhibitor; antileukemic; "Administration of JTE-607 using osmotic pumps reduced the number of leukemic cells...and significantly prolonged the mouse survival..." p. 1386.

P8294 Yagi,H., Ueda,M., Jinno,H., Aiura,K., Mikami,S., Tada,H., Seno,M., Yamada,H., Kitajima,M. Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. CANCER SCIENCE 2006; 97(-12-):1315-1320. >>> Fibroblast growth factor, basic; CL-RFN89; PBS; Mice (nude); ; Cancer (carcinoma); animal info (4 weeks old, female, Balb/C, nude); antiangiogenesis; tumor cells in right flank, agent is an insertional-fusion protein.

P8289 Banach-Petrosky,W., Ouyang,X.S., Gao,H., Nader,K., Ji,Y., Suh,N., DiPaola,R.S., bate-Shen,C. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice. Clinical Cancer Research 2006; 12(-19-):5895-5901. >>> Vitamin D3, 1,25-dihydroxy-; Propylene glycol; SC; Mice; 2004; 1-4 months; Controls received mp w/ vehicle; long-term study; pumps replaced every 4 weeks; stability verified by serum calcium levels; cancer (prostate); animal info (4-7 months old, male).

P8286 Ying,H., Biroc,S.L., Li,W.W., Alicke,B., Xuan,J.A., Pagila,R., Ohashi,Y., Okada,T., Kamata,Y., Dinter,H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. MOLECULAR CANCER THERAPEUTICS 2006; 5(-9-):2158-2164. >>> Fasudil; Saline; SC; Mice (nude); 21 days; Controls received mp w/ vehicle; cancer (lung).

P8271 Strieth,S., Eichhorn,M.E., Sutter,A., Jonczyk,A., Berghaus,A., Dellian,M. Antiangiogenic combination tumor therapy blocking alpha v-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. International Journal of Cancer 2006; 119(-2-):423-431. >>> EMD270179; SU5416; DMSO; HCL; SC; IP; Hamster; 2001; 7 days; Controls received mp w/ vehicle; functionality of mp verified by EMD270179 plasma levels; no stress (see pg. 425); half-life (p. 427); "In consideration of the short half-lives of cRGD peptides we decided to apply antiangiogenic cRGD peptides continuously by osmotic pumps." cancer (A-Mel-3); peptides; animal info (syrian golden, 6-8 weeks old, 60 grams); 50% DMSO used; "All animals tolderated pump placement well...in all animals receiving IP osmotic pumps we found quite consistent plasma levels on days 1, 4, 6, and 7 after pump implantation." (p. 425).

P8244 Redjal,N., Chan,J.A., Segal,R.A., Kung,A.L. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clinical Cancer Research 2006; 12(-22-):6765-6771. >>> AMD3100; PBS; SC; Mice; 15 days; Controls received mp w/ vehicle; comparison of SC injections vs. mp; cancer (glioma); bioluminescence, IVIS imaging system; combination therapy; CXCR4 inhibitor.

P8209 Masunaga,S.I., Kasaoka,S., Maruyama,K., Nigg,D., Sakurai,Y., Nagata,K., Suzuki,M., Kinashi,Y., Maruhashi,A., Ono,K. The potential of transferrin-pendant-type polyethyleneglycol liposomes encapsulating decahydrodecaborate-10B (GB-10) as 10B-carriers for boron neutron capture therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2006; 66(-5-):1515-1522. >>> Uridine, bromodeoxy-; Saline, physiological; SC; Mice; 5 days; Cancer (squamous cell carcinoma); animal info (female, C3H/He, 8-11 wks old, 20-25g.).

P8208 Martens,T., Schmidt,N.O., Eckerich,C., Fillbrandt,R., Merchant,M., Schwall,R., Westphal,M., Lamszus,K. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clinical Cancer Research 2006; 12(-20-):6144-6152. >>> Antibody, anti-c-Met, OA5D5; Histidine; CSF/CNS (intratumoral); Mice (nude); 2004; 12, 21, 28 days; Controls received mp w/ vehicle; cancer (glioblastoma); ALZET brain infusion kit 2 used; animal info (male, NMRI-nu/nu, 6-8 wks old); "Because the OA-5D5 antibody is a relatively large but stable molecule, convection-enhanced drug delivery (by mp) was ideally suited to deliver it in our orthotopic model." (p.6151); tissue perfusion (tumor).

P8169 Masunaga,S.I., Uto,Y., Nagasawa,H., Hori,H., Nagata,K., Suzuki,M., Kinashi,Y., Ono,K. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. dependency on p53 status of tumor cells and the effects on intratumor quiescent cells. Anticancer Research 2006; 26(-2A-):1261-1270. >>> Uridine, bromodeoxy, 5-; Saline, physiological; SC; Mice (nude); 5, 7 days; Cancer (squamous cell carcinoma); animal info (BALB/cA, C3H/He, 6-7 weeks old, 22 grams); labeling of tumor 'P' cells.

P8159 Bihorel,S., Camenisch,G., Gross,G., Lemaire,M., Scherrmann,J.M. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug Metabolism and Disposition 2006; 34(-12-):1945-1949. >>> Imatinib mesylate; hydroxyurea; Saline; SC; Rat; 2ML2; 7, 14 days; Half-life (p. 1948) hydroxyurea<1 hour in rats; enzyme inhibitor (ribonucleotide reductase); cancer (glioblastoma); animal info (Hanover Wistar, 270-310 grams); ATP competitive inhibitor; A.K.A, Gleevec or STI571.

P8145 Grommes,C., Landreth,G.E., Sastre,M., Beck,M., Feinstein,D.L., Jacobs,A.H., Schlegel,U., Heneka,M.T. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. MOLECULAR PHARMACOLOGY 2006; 70(-5-):1524-1533. >>> Pioglitazone; DMSO; PBS; CSF/CNS (intratumoral); Rat; 2ML4; 3, 6, 9, 14, 21 days; Controls received mp w/ vehicle; comparison of oral admin. vs. mp; no stress (see p.1532); stability verified by in vitro incubation at 37 celsius for 21 days; cancer (glioma); ALZET brain infusion kit used; animal info (Sprague-Dawley, 200-250g.); 0.1% DMSO; Antineoplastic; tissue perfusion (tumor).

P8140 Husen,B., Huhtinen,K., Saloniemi,T., Messinger,J., Thole,H.H., Poutanen,M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006; 147(-11-):5333-5339. >>> B10721325; estrone; DMSO; propanediol; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (p.5335); pumps replaced after 14 days; enzyme inhibitor (hydroxysteroid 17 beta dehydrogenase 1); cancer (breast); animal info (female, BALB/cA Bom-v, Crl: nu/nu, 10-11 wks old); 50%DMSO; endocrinology.

P8109 Dirkx,A.E.M., Egbrink,M.G.A.O., Castermans,K., van der Schaft,D.W.J., Thijssen,V.L.J.L., Dings,R.P.M., Kwee,L., Mayo,K.H., Wagstaff,J., Steege,J.C.A.B., Griffioen,A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB Journal 2006; 20(-6-):621-630. >>> Anginex; endostatin; BSA; angiostatin; Saline; SC; Mice; 2 weeks; 7, 11 days; Controls received mp w/ BSA or no treatment; dose-response (fig.5); cancer (melanoma, colon carcinoma); animal info (C57BL/6).

P8052 Brown,J.R., Fuster,M.M., Li,R.X., Varki,N., Glass,C.A., Esko,J.D. A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clinical Cancer Research 2006; 12(-9-):2894-2901. >>> Disaccharide, AcGnG-NM; DMSO; propylene glycol; SC; Mice; 2004; 2, 4 weeks; Controls received mp w/ vehicle; stability verified by incubation in mouse serum; cancer (lung carcinoma, B16Bl6 melanoma); animal info (c57BL/6 Es1(e); 8-12 wk old, lung metastases); 50% DMSO.

P8018 Kim,K.S., Sengupta,S., Berk,M., Kwak,Y.G., Escobar,P.F., Belinson,J., Mok,S.C., Xu,Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Research 2006; 66(-16-):7983-7990. >>> Lysophosphatidic acid; PBS; IP; Mice (nude); 1002; 21 days; Controls received mp w/ vehicle; pumps replaced every 15 days; cancer (ovarian carcinoma); animal info (female, nu/nu, skov3 tumors placed on ovaries); mp siliconized by placing 100 ul sigmacote into mp, removing liquid and letting the mp dry before agent is introduced; developed mouse model of metastatic ovarian cancer.

P8002 Tsai,C.H., Hong,J.H., Hsieh,K.F., Hsiao,H.W., Chuang,W.L., Lee,C.C., McBride,W.H., Chiang,C.S. Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer. Cancer Gene Therapy 2006; 13(-12-):1082-1092. >>> Doxycycline; PBS; SC; Mice; 2001; 7 days; Controls received mp w/ vehicle; cancer (prostate); animal info (C57BL/6J, 7-8 weeks old); paper states incorrect pump model.

P7999 Ueda,S., Nakamura,T., Yamada,A., Teratani,A., Matsui,N., Furukawa,S., Hoshino,Y., Narita,M., Yodoi,J., Nakamura,H. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. LIFE SCIENCES 2006; 79(-12-):1170-1177. >>> Thioredoxin, human recomb.; SC; Mice (nude); 2002; 2 weeks; Controls received mp w/ PBS; plasma levels taken; cancer (colon, carcinoma); peptides; animal info (female, 6 weeks old, nude); xenograft.

P7965 O'Connor,O.A., Smith,E.A., Toner,L.E., Teruya-Feldstein,J., Frankel,S., Rolfe,M., Wei,X.H., Liu,S.J., Marcucci,G., Chan,K.K., Chanan-Khan,A. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clinical Cancer Research 2006; 12(-9-):2902-2911. >>> Oblimersen; Saline; SC; Mice (SCID); 2004; 28 days; Stress/adverse reaction: (see pg. 2907), infection (pumps are provided sterile); cancer (lymphoma); animal info (5-7 weeks old, SCID); xenograft; bcl-2 antisense molecule.

P7944 Shao,T.C., Li,H.L., Kasper,S., Matusik,R., Ittmann,M., Cunningham,G.R. Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-Tag transgenic mice. PROSTATE 2006; 66(-4-):369-376. >>> Testosterone; nortestosterone, 7 alpha-methyl-19-; Cyclodextrin; SC; Mice (transgenic); 2004; 4 weeks; Replacement therapy (orchidectomy); cancer (prostate); animal info (male, transgenic, 32 grams, ORX); MENT (7-alpha-methyl-19-nor-testosterone) and testosterone dissolved in 45% cyclodextrin.

P7935 Chen,J.C., Chen,Y., Wu,J.M., Su,Y.H., Tai,K.F., Tseng,S.H. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats. CANCER IMMUNOLOGY IMMUNOTHERAPY 2006; 55(-7-):873-883. >>> Granulocyte-macrophage colony-stimulating factor, recomb. mouse; interleukin-12, recomb. mouse; BSA; PBS; SC; Rat; 2002; 14 days; Controls received mp w/ vehicle or no treatment; cancer (RT-2 glioma); peptides; animal info (Fischer, 200-350 grams, SC and ICV tumors); "continuously infused cytokine using an osmotic mini pump to...avoid the side effects of a single large dose of cytokine and one with a concept similar to that of gene-therapy." (p. 874).

P7922 Segrelles,C., Moral,M., Lara,M.F., Ruiz,S., Santos,M., Leis,H., Garcia-Escudero,R., Martinez-Cruz,A.B., Martinez-Palacio,J., Hernandez,P., Ballestin,C., Paramio,J.M. Molecular determinants of Akt-induced keratinocyte transformation. ONCOGENE 2006; 25(-8-):1174-1185. >>> Rapamycin; PBS; BSA; SC; Mice (nude); 2002; 2 weeks; Cancer; animal info (nude, 5-6 weeks old, female).

P7906 Houli,N., Loh,S.W., Giraud,A.S., Baldwin,G.S., Shulkes,A. Mitogenic effects of both amidated and glycine-extended gastrin-releasing peptide in defunctioned and azoxymethane-treated rat colon in vivo. REGULATORY PEPTIDES 2006; 134(-1-):9-16. >>> Gastrin-releasing peptide, amidated; gastrin-releasing peptide, glycine extended; PBS; IP; Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; no stress (see pg. 11-12); cancer (colorectal); peptides; animal info (male, Sprague-Dawley, 250-350g); "All animals remained healthy during the 4 week experimental period and rats in the different experimental groups gained weight at the same rate." (p. 11-12).

P7905 Shir,A., Ogris,M., Wagner,E., Levitzki,A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLOS MEDICINE 2006; 3(-1-):125-135. >>> RNA, double stranded; polyinosine-cytosine (poly IC) dsRNA; Non-viral vector; SC; Mice; 2001D; 2 days; Per communication with author on 8/11/07, "We did not have any particular problems with the anesthesia exposure. For the pump replacement procedure Ketamine/Xylazine 2% (0.85ml/0.15ml), 40-50 ul IP per mouse (25 gram) was used. Replacing of the pump was not problematic either. The skin was closed with a surgical clips which are less traumatic to the mice and are easily applied and removed." 2001D pump replaced every day for two days total duration; synthetic dsRNA was attached to a non-viral vector (PEI-PEG-EGF beta PEI-Mel complexes) with specificity to the epidermal growth factor receptor (EGFR); controls received vector only (no poly IC); tissue perfusion (intratumoral); cancer (glioblastoma, breast, adenocarcinoma).

P7904 Harding,T.C., Lalani,A.S., Roberts,B.N., Yendluri,S., Luan,B., Koprivnikar,K.E., Gonzalez-Edick,M., Guang,H.T., Musterer,R., VanRoey,M.J., Ozawa,T., LeCouter,R.A., Deen,D., Dickinson,P.J., Jooss,K. AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. MOLECULAR THERAPY 2006; 13(-5-):956-966. >>> Adeno-associated virus serotype 8 vector, recomb.; CSF/CNS (intratumoral); Rat; 2001D; 24 hours; Controls received mp w/ AAV control; cancer (glioblastoma multiforme, u-251 MG); gene thrapy; animal info (male, athymic, 6 wk. old); rAAV contains soluble VEGF inhibitor, sVEGFR1/R2; "Implantation of the mini pump allows the slow infusion of a rAAV vector...to transduce more effectively the intracranial tumor mass." (pg. 962); antiangiogenesis.

P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.

P7880 Lucattelli,M., Fineschi,S., Geppetti,P., Gerard,N.P., Lungarella,G. Neurokinin-1 receptor blockade and murine lung tumorigenesis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2006; 174(-6-):674-683. >>> L-733,060; Water, sterile; SC; Mice; 2002; 2 weeks; Controls received mp w/ vehicle; cancer (adenocarcinoma); animal info (Balb/c, C57BL/6, NK1r -/-, bleomycin-induced pulmonary fibrosis, 8-16 wk old); NK-1R antagonist.

P7848 Menu,E., Asosingh,K., Indraccolo,S., De Raeve,H., Van Riet,I., Van Valckenborgh,E., Broek,I.V., Fujii,N., Tamamura,H., Van Camp,B., Vanderkerken,K. The involvement of stromal derived factor 1 alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica-The Hematology Journal 2006; 91(-5-):605-612. >>> TN14003, 4F-benzoyl-; Saline; SC; Mice; 2004; 3 weeks; Controls received mp w/ vehicle; cancer (myeloma, bone marow); animal info (C57BL/KaLwRij, 8-10 wk. old); CXCR4 inhibitor.

P7840 Choi,J., Credit,K., Henderson,K., Deverkadra,R., He,Z., Wiig,H., Vanpelt,H., Flessner,M.F. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration. Clinical Cancer Research 2006; 12(-6-):1906-1912. >>> Immunoglobulin G, donkey anti-rabbit; radio-isotopes; Kreb's solution; bicarbonate; ringer's solution; sodium azide; 125I tracer; IV (jugular); Rat (nude); 2001; 5-7 days; Cancer (metastatic ovarian carcinoma); animal info (RNU-nude, athymic, 150-180g.).

P7807 Jung,F.H., Pasquet,G., Lambert-van der Brempt,C., Lohmann,J.J.M., Warin,N., Renaud,F., Germain,H., De Savi,C., Roberts,N., Johnson,T., Dousson,C., Hill,G.B., Mortlock,A.A., Heron,N., Wilkinson,R.W., Wedge,S.R., Heaton,S.P., Odedra,R., Keen,N.J., Green,S., Brown,E., Thompson,K., Brightwell,S. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. Journal of Medicinal Chemistry 2006; 49(-3-):955-970. >>> Thiazoloquinazoline, compound 54; Tris buffer; SC; Mice (nude); 2001D; 48 hours; Controls received mp w/ vehicle; half-life (pg. 963) 0.7 hours in mouse plasma; enzyme inhibitor (aurora A/B kinase); cancer (colorectal carcinoma); animal info (Swiss nu/nu, male, 8-10 wk old).

P7800 Palm,D., Lang,K., Niggemann,B., Drell,T.L., Masur,K., Zaenker,K.S., Entschladen,F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by betablockers. International Journal of Cancer 2006; 118(-11-):2744-2749. >>> Norepinephrine; propranolol; Saline, physiological; ascorbic acid; SC; Mice (nude); 1002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; half-life (pg. 2745) short, quickly metabolized; cancer (prostate carcinoma); animal info (female, BALB/C nude, athymic, 6 wk. old, 15g.).

P7780 Gu,L.Z., Hu,W.Y., Antic,N., Mehta,R., Turner,J.R., de Lanerolle,P. Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. European Journal of Cancer 2006; 42(-7-):948-957. >>> ML-7; DMSO; SC; Mice; 2004; 4 weeks; Controls received mp w/ vehicle; no stress (see pg. 952, 955); enzyme inhibitor (myosin light chain kinase); cancer (mammary adenocarcinoma); toxicology; animal info (female, 14-20 wk. old, MMTV-free, C3H/Hen); 50% DMSO.

P7768 Damber,J.E., Vallbo,C., Albertsson,P., Lennernaes,B., Norrby,K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemotherapy and Pharmacology 2006; 58(-3-):354-360. >>> Cyclophosphamide; paclitaxel; Saline; SC; Rat; 2ML1; 10 days; Controls received mp w/ vehicle; cancer (AT-1 adenocarcinoma); animal info (adult, male, copenhagen); "Continuous/metronomic therapy may achieve a more pronounced anti-tumoural effect and significantly diminish the side effects compared with conventional bolus MTD-type chemotherapy." (p. 359).

P7766 Takakura,T., Takimoto,A., Notsu,Y., Yoshida,H., Ito,T., Nagatome,F., Ohno,M., Kobayashi,Y., Yoshioka,T., Inagaki,K., Yagi,S., Hoffman,R.M., Esaki,N. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine -lyase conjugated with polyethylene glycol as an antitumor agent. Cancer Research 2006; 66(-5-):2807-2814. >>> Pyridoxal 5'-phosphate; Sodium phosphate buffer; SC; Mice; 2001; 3 days; Functionality of mp verified by plasma PLP concentrations; cancer; animal info (BALB/c AnNCrj, female, 8-10 wk old, 20-22g); "we believe that DTT-treated PEG-METase should be used together with PLP infusion to minimize the dose&frequency of administration to increase efficacy" (p.2813).

P7755 Aghi,M., Cohen,K.S., Klein,R.J., Scadden,D.T., Chioccra,E.A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Research 2006; 66(-18-):9054-9064. >>> AMD 3100; SC; Mice; mice (transgenic); 2002; 17 days; Controls received mp w/ PBS; comparison of short-term IV injections vs. mp; cancer (astrocytoma, glioma); animal info (C57BL/6, WT); SDF-1R CXCR4 antagonist.

P7748 Huang,X.L., Brown,C., Ni,W.H., Maynard,E., Rigby,A.C., Oettgen,P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006; 107(-8-):3153-3160. >>> Peptide A1; peptide A1, mutant; PBS; SC; Mice (nude); 10,14 days; Controls received mp w/ vehicle; no stress (see pg. 3157); cancer (B16 melanoma); peptides; animal info (C57BL/6, female); peptide A1 is composed of ETS sequences and a 12-amino acid HIV-TAT protein-transducing membrane peptide.

P7694 Michl,J., Scharf,B., Schmidt,A., Huynh,C. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. International Journal of Cancer 2006; 119(-7-):1577-1585. >>> PNC-28; PBS, sterile; SC; IP; Mice (nude); 1002; 2 weeks; Controls received mp w/ control peptide; cancer (pancreatic); peptides; animal info (Nu/Nu, 7-8 weeks old, 22-24 g); xenotransplant tumor cells in hindleg or IP; additional mice had IP pumps; "...PNC-28 may be effective in treating cancers especially if delivered directly to the tumor." (p. 1577).

P8287 Manabe,T., Okino,H., Maeyama,R., Mizumoto,K., Tanaka,M., Matsuda,T. New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: Potential use for suppression of local recurrence of pancreatic cancer. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS 2005; 73B(-1-):203-207. >>> Gemcitabine; SC; Mice (nude); 1007D; 7 days; Tissue perfusion (intratumoral); comparison of IP injections; cancer (pancreatic); animal info (five week old); pump used as part of a novel infusion device; pictures of device p. 205; PE tubing used to connect pump to perfusion device; continuous infusion resulted in macroscopically undetectable tumors after day 6.

P8173 Marchal,F., Tran,N., Marchal,S., Leroux,A., Marchal,C., Bolotine,L., Guillemin,F.O., Villemot,J.P. Development of an HT29 liver metastases model in nude rats. Oncology Reports 2005; 14(-5-):1203-1207. >>> Cyclosporin A; IP; Rat (nude); 2ML4; 4 weeks; Controls received no treatment; no stress (see pg. 1204); cancer (colorectal); peptides; animal info (male, athymic Rowett nude, 300 grams).

P8162 Tjomsland,V., El-Salhy,M. Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer. INTERNATIONAL JOURNAL OF ONCOLOGY 2005; 27(-2-):427-432. >>> Octreotide; galanin, synthetic human; serotonin; IP; Mice (nude); 1002; 14 days; No stress (see pg. 429); cancer (colon); animal info (female, BALB/cA-nu, 6-8 weeks old, 20 grams); "The animals treated with triple therapy (mp) did not show any sign of discomfort or suffering during the experiment and held a stable body weight." (p. 429).

P8051 Wang,J.R., Zheng,H., Qiu,X.H., Kulkarni,A., Fink,L.M., Hauer-Jensen,M. Modulation of the intestinal response to ionizing radiation by anticoagulant and non-anticoagulant heparins. THROMBOSIS AND HAEMOSTASIS 2005; 94(-5-):1054-1059. >>> Nadroparin; sr-80258a; Saline, physiological; SC; Rat; 2002; 17 days; Controls received mp w/ vehicle; half-life (p.1055) 3.5 hrs. (nadroparin); cancer (radiation therapy); cardiovascular; toxicology; animal info (male,Sprague-Dawley, 43-49 days old, 175-200 grams, small bowel irradiation).

P7975 Pyrko,P., Wang,W., Markland,F.S., Swenson,S.D., Schmitmeier,S., Schonthal,A.H., Chen,T.C. The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. Journal of Neurosurgery 2005; 103(-3-):526-. >>> Contortrostatin; CSF/CNS (intratumorally); Mice; 2 weeks; Controls received mp w/ PBS; plasma levels taken; cancer (glioma); brain tissue distribution; snake venom disintegrin; "agent was well tolerated by animals and lacks obvious neurotoxic side effects. All the contortrostatin treated mice survived the entire treatment period and continued to do well for seven more days after the termination." p. 533; tygon tubing used; tissue perfusion (tumor).

P7931 Yurimoto,S., Miyakawa,A., Okuzawa,A., Sakamoto,S., Sakamoto,K., Hosoda,S., Kamano,T. Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model. Anti-cancer Drugs 2005; 16(-10-):1109-1114. >>> Fluorouracil, 5-FU; IP; Mice; 1007D; 8 days; Cancer (sarcoma-180); animal info (six week old, male, 30 grams); tumor cells in abdomen; chemotherapeutic.

P7774 Saba,S.R., Garces,A.H., Clark,L.C., Soto,J., Gower,WR Jr, Vesely,D.L. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. JOURNAL OF HISTOCHEMISTRY&CYTOCHEMISTRY 2005; 53(-8-):989-995. >>> Atrial natriuretic peptide; vessel dilataor peptide; kaliuretic peptide; natriuretic peptide, long-acting; Mice (nude); 2004; 4 weeks; Cancer (panceatic adenocarcinoma); peptides; animal info (athymic).

P7764 Pukac,L., Kanakaraj,P., Humphreys,R., Alderson,R., Bloom,M., Sung,C., Riccobene,T., Johnson,R., Fiscella,M., Mahoney,A., Carrell,J., Boyd,E., Yao,X.T., Zhang,L., Zhong,L., von Kerczek,A., Shepard,L., Vaughan,T., Edwards,B., Dobson,C., Salcedo,T., Albert,V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer 2005; 92(-8-):1430-1441. >>> Fluorouracil, 5-; SC; Mice (nude); 2002; 14 days; Controls received no treatment; cancer (colon); animal info (female, Swiss, athymic, 7-8 wk old, 20g.).

P7673 Dragonas,C., Mueller,A., Maltaris,T., Kraemer,P., Dimmler,A., Jaeger,W., Beckmann,M.W., Dittrich,R. Role of insulin in the progression of ovarian sex cord stromal tumors in rats. Journal of Cancer Research and Clinical Oncology 2005; 131(-11-):751-757. >>> Insulin; SC; Rat; 28, 56, 84 days; Controls received mp w/ saline; replacement therapy (ovariectomy, STZ-induced diabetes); long-term study; pumps replaced every 28 days; no stress (see pg.753); cancer (sex cord stomal); animal info (female, Lewis, 60 days old, 150-210 g).

P7653 Wiig,H., Gyenge,C.C., Tenstad,O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. JOURNAL OF PHYSIOLOGY-LONDON 2005; 567(-2-):557-567. >>> Herceptin; immunoglobulin G, 1-; Radio-isotopes; 125I tracer; 131I tracer; IV (jugular); Rat; 2001; 5-7 days; Cancer (mammary); animal info (female, Sprague-Dawley, 208-255 g).

P7612 Gupta,A.K., Cerniglia,G.J., Mick,R., McKenna,W.G., Muschel,R.J. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Research 2005; 65(-18-):8256-8265. >>> Amprenavir; SC; Mice (nude); 1-4, 2-15 days; Controls received mp w/ vehicle; functionality of mp verified by serum drug levels by HPLC; no stress (see pg.826); enzyme inhibitor (HIV protease); cancer (SQ208, head and neck, T24 bladder); animal info (female, Ncr- nu/nu); irradiation.

P7593 Kaufmann,W., Mellert,W., van Ravenzwaay,B., Landsiedel,R., Poole,A. Effects of styrene and its metabolites on different lung compartments of the mouse - cell proliferation and histomorphology. Regulatory Toxicology and Pharmacology 2005; 42(-1-):24-36. >>> Uridine, bromodeoxy-; Saline; SC; Mice; 2001; ; Cancer; toxicology; animal info (female, CD1, 49 days old); labeling of lung cells.

P7549 Munoz-de-Toro,M., Markey,C.M., Wadia,P.R., Luque,E.H., Rubin,B.S., Sonnenschein,C., Soto,A.M. Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. Endocrinology 2005; 146(-9-):4138-4147. >>> Bisphenol A; estradiol; DMSO; SC; Mice (pregnant); 10, 14 days; Controls received mp w/ vehicle; dose-response (fig. 1); cancer (mammary); teratology; animal info (female, CD-1, 9 wk old).

P7444 Green,T., Toghill,A., Lee,R., Waechter,F., Weber,E., Noakes,J. Thiamethoxam induced mouse liver tumors and their relevance to humans - Part 1: Mode of action studies in the mouse. TOXICOLOGICAL SCIENCES 2005; 86(-1-):36-47. >>> Uridine, bromodeoxy-; Sodium bicarbonate; SC; Mice; 1003D; 3 days; Cancer (hepatic); toxicology; animal info (male, 30-43 g); labeling of hepatocytes.

P7441 Green,T., Toghill,A., Lee,R., Waechter,F., Weber,E., Peffer,R., Noakes,J., Robinson,M. Thiamethoxam induced mouse liver tumors and their relevance to humans - Part 2: Species differences in response. TOXICOLOGICAL SCIENCES 2005; 86(-1-):48-55. >>> Uridine, bromodeoxy-; Sodium bicarbonate; SC; Rat; 2ML1; 3 days; Cancer (hepatic); toxicology; animal info (female, 140-160 g).

P7435 Gross,S., Piwnica-Worms,D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. NATURE METHODS 2005; 2(-8-):607-614. >>> Luciferin, D-; SC; Mice; 1007D; ; Cancer; bioluminescence imaging (BLI); IVIS; animal info (balb/c, 6 weeks old, male); "By eliminating constraints of intraperitoneal (i.p.) bolus reinjections of substrate, the implanted pump allowed continuous real-time molecular imaging of reporter activity throughout the time course of a multi-day experiment, while simultaneously allowing rapid temporally resolved analysis of short time constants that characterize drug action. This innovation should be generalizable to a variety of other imaging strategies in vivo." P. 613.

P7434 Kawakami,K., Kioi,M., Liu,Q., Kawakami,M., Puri,R.K. Evidence that IL-13R alpha-2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. Journal of Immunotherapy 2005; 28(-3-):193-202. >>> Interleukin-13-PE38; interleukin-13Ra2, pME18S-; CSF/CNS (intratumoral); Mice (nude); 1003D; 1007D; 7 days; Controls received mp w/ vehicle or antisense IL-13Ra2 plasmid vector; pumps replaced after 3 days; cancer (glioblastoma); cyanoacrylate adhesive; convection enhanced delivery; IL-13Ra2 cDNA encoding plasmid vector; "the upregulated IL-13 Ra2 chain was successfully targeted with a continuous infusion of IL-13 cytotoxin." (p. 199).

P7417 Schmidt,N.O., Przylecki,W., Yang,W., Ziu,M., Teng,Y., Kim,S.U., Black,P.M., Aboody,K.S., Carroll,R.S. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. NEOPLASIA 2005; 7(-6-):623-629. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice; 2004; ; Controls received mp w/ PBS; functionality of mp verified by residual volume; cancer.

P7394 Guarnieri,M., Carson,B.S., Khan,A., Penno,M., Jallo,G.I. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. Journal of Neuroscience Methods 2005; 144(-2-):147-152. >>> Doxorubicin; carboblatin; Dextrose solution; saline; CSF/CNS (parenchyma); Rat; 2001; ; Animal info (F, Fischer, 220 g); Functionality of mp verified by pump examination, post infusion; stability verified by previous studies, 14 days; good methods (p. 148); cancer (glioma); brain tissue distribution; Plastics One cannula used (stainless steel); "replacement of rigid infusion tubes [cannulae] with flexible tubing increases the reliability of local CNS drug infusions. Rigid catheters [cannulae] may allow backflow of the infused drug along the path of the catheters into the subdural space." (P. 147).

P7388 Arcella,A., Carpinelli,G., Battaglia,G., D'Onofrio,M., Santoro,F., Ngomba,R.T., Bruno,V., Casolini,P., Giangaspero,F., Nicoletti,F. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. NEURO-ONCOLOGY 2005; 7(-3-):236-245. >>> LY341495; ethylglutamate, alpha-25; Saline; SC; Mice (nude); 1007D; 2004; 7, 28 days; Controls received mp w/ vehicle; cancer (glioma); mGlu 2/3 receptor antagonist; pumps removed prior to MRI.

P7357 Nakagawa,H., Yoshioka,K., Miyahara,E., Fukushima,Y., Tamura,M., Itoh,K. Intrathecal administration of Y-27632, a specific Rho-associated kinase inhibitor, for rat neoplastic meningitis. MOLECULAR CANCER RESEARCH 2005; 3(-8-):425-433. >>> Y-27632; uridine, fluorodeoxy-; PBS; CSF/CNS (Intrathecal, cisterna magna); Rat; 2002; ; Cancer (breast); enzyme inhibitor (rho-associated kinase inhibitor).

P7322 Dings,R.P.M., Williams,B.W., Song,C.W., Griffioen,A.W., Mayo,K.H., Griffin,R.J. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. International Journal of Cancer 2005; 115(-2-):312-319. >>> Anginex; PBS; SC; Mice (nude); 2002; 2004; 2, 4 weeks; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 315); half-life (p. 318) 50-90 min. in mice; cancer (ovarian, mammary carcinoma); toxicology; peptides; irradiation 5 Gy once per week or 25 Gy one time tumo-bearing legs; angiogenesis inhibitor; "continuous infusion of anginex in combination with weekly irradiation resulted in tumor regression and impalpable tumors by the end of treatment." P317.

P7321 Aparicio,T., Kotelevets,L., Tsocas,A., Laigneau,J.P., Sobhani,I., Chastre,E., Lehy,T. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in ApcMin/+ mice. Gut 2005; 54(-8-):1136-1145. >>> Leptin, recomb. human; leptin, recomb. murine; Saline, BSA; SC; Mice (nude); mice; 2002; 4, 6 weeks; Controls received mp w/ vehicle; functionality of mp verified by plasma leptin levels; pumps replaced every 2 weeks; cancer (colon, intestinal adenoma); peptides.

P7307 Nakagawa,K., Sasaki,Y., Kato,S., Kubodera,N., Okano,T. 22-oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005; 26(-6-):1044-1054. >>> Vitamin D3, 1, 25-dihydroxy-; vitamin D3, 22-oxa-la, 25-dihydroxy-; Tween 20; ethanol; SC; Mice; 2ML4; 3 weeks; 10, 18 days; Controls received mp w/ vehicle; dose-response; cancer (lung carcinoma); 10% ethanol; millipore chamber ring; sc dorsal air sac model.

P7287 Guba,M., Koehl,G.E., Neppl,E., Doenecke,A., Steinbauer,M., Schlitt,H.J., Jauch,K.W., Geissler,E.K. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. TRANSPLANT INTERNATIONAL 2005; 18(-1-):89-94. >>> Rapamycin; DMSO; IP; Mice; 2002; 7-35 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; cancer (colon adenocarcinoma); "The most effective inhibition of tumor growth occurred in rapamycin-treated mice on the continuous pumping system.;" "Survival data also show the most positive effect with continuous drug delivery." P. 91.

P7283 Ozawa,T., Afzal,J., Lamborn,K.R., Bollen,A.W., Bauer,W.F., Koo,M.S., Kahl,S.B., Deen,D.F. Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2005; 63(-1-):247-252. >>> Porphyrin, boronated; PBS; CSF/CNS (intratumoral); Rat; 2001D; 24 hours; Controls received no treatment; dose-response; comparison of IV injections vs. mp; cancer (brain glioma); toxicology.

P7278 Lobo,E.D., Balthasar,J.P. Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. Journal of Pharmaceutical Sciences 2005; 94(-9-):1957-1964. >>> Methotrexate; IP; Mice; 1003D; 72 hours; Controls received ip bolus saline injection; dose-response (fig. 3); cancer (peritoneal sarcoma); toxicology; mp primed overnight in 37 degrees saline.

P7271 Kashiwagi,S., Izumi,Y., Gohongi,T., Demou,Z.N., Xu,L., Huang,P.L., Buerk,D.G., Munn,L.L., Jain,R.K., Fukumura,D. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. Journal of Clinical Investigation 2005; 115(-7-):1816-1827. >>> L-NMMA; D-NMMA; SC; Mice; mice (SCID); 1002; 8, 21 days; Controls received mp w/ D-NMMA; pumps replaced at day 14; enzyme inhibitor (NO synthase); cancer (melanoma); cardiovascular; eNOS -/- mice; iNOS -/- mice.

P7269 Huss,W.J., Gray,D.R., Greenberg,N.M., Mohler,J.L., Smith,G.J. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Research 2005; 65(-15-):6640-6650. >>> Uridine, bromodeoxy-; Mice (transgenic); 2002; 2 weeks; Cancer (prostate); labeling of the prostate.

P7267 Fluiter,K., Frieden,M., Vreijling,J., Rosenbohm,C., de Wissel,M.B., Christensen,S.M., Koch,T., Orum,H., Baas,F. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. CHEMBIOCHEM 2005; 6(-6-):1104-1109. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, amino-LNA antisense; oligodeoxynucleotide, thio-LNA antisense; oligodeoxynucleotide, LNA antisense; oligodeoxynucleotide, missense; SC; Mice (nude); 1002; 11 days; 48 hours; Controls received mp w/ saline; dose-response (fig. 4); no stress (see pg. 1106); stability verified by incubation in human serum; antisense (H-Ras); cancer (prostate).

P7261 Nakano,K., Todo,T., Zhao,G., Yamaguchi,K., Kuroki,S., Cohen,J.B., Glorioso,J.C., Tanaka,M. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. JOURNAL OF GENE MEDICINE 2005; 7(-5-):638-648. >>> Fluorouracil, 5-; IP; Mice (SCID); hamster; 2 weeks; Cancer (gastric, gall bladder carcinoma); pyrimidine synthesis inhibitor.

P7250 Liu,T., Bohlken,A., Kuljaca,S., Lee,M., Nguyen,T., Smith,S., Cheung,B., Norris,M.D., Haber,M., Holloway,A.J., Bowtell,D.D.L., Marshall,G.M. The retinoid anticancer signal: mechanisms of target gene regulation. British Journal of Cancer 2005; 93(-3-):310-318. >>> Retinoic acid, 13-cis-; Ethanol; SC; Mice (transgenic); 1007D; 5 weeks; Controls received mp w/ vehicle; dose-response (fig. 1); no stress (see pg. 312-13); cancer (neuroblastoma).

P7248 Lakka,S.S., Gondi,C.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,V.H., Sioka,C., Rao,J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. Journal of Biological Chemistry 2005; 280(-23-):21882-21892. >>> RNA, small interfering; RNA, small interfering, uPAR; RNA, small interfering, MMP-9; CSF/CNS; Mice (nude); 1002; 2 weeks; Controls received mp w/ PBS or empty vector; cancer (glioblastoma); siRNA is within a plasmid vector (pUM vector); antiangiogenesis; gene therapy.

P7233 Haviv,F., Bradley,M.F., Kalvin,D.M., Schneider,A.J., Davidson,D.J., Majest,S.M., McKay,L.M., Haskell,C.J., Bell,R.L., Nguyen,B., Marsh,K.C., Surber,B.W., Uchic,J.T., Ferrero,J., Wang,Y.C., Leal,J., Record,R.D., Hodde,J., Badylak,S.F., Lesniewski,R.R., Henkin,J. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. Journal of Medicinal Chemistry 2005; 48(-8-):2838-2846. >>> ABT-510; Dextrose solution; water; SC; Mice; 2001; 7, 14 days; Controls received mp w/ vehicle; dose-response (fig. 6); half-life (p. 2838); cancer (lung carcinoma); peptides.

P7232 Karam,S.M., John,R., Alpers,D.H., Ponery,A.S. Retinoic acid stimulates the dynamics of mouse gastric epithelial progenitors. Stem Cells 2005; 23(-3-):433-441. >>> Retinoic acid; uridine, bromodeoxy-; SC; Mice; 1, 3, 6 days; Controls received mp w/ vehicle; comparison of SC injections vs. mp; cancer (gastric); multiple pumps per animal (2).

P7197 MacKay,J.A., Deen,D.F., Szoka,FC Jr  Brain Research 2005; 1035(-2-):139-153. >>> Liposomes; FITC-dextran-lysine; Saline; tris buffer; CSF/CNS (caudate putamen); CSF/CNS (intratumoral); Rat; 2001D; 24 hours; Tissue perfusion (intratumoral); comparison of acute CSF/CNS injection vs. mp; half-life (p. 151) 9.9 hours; cancer (glioblastoma); ALZET brian infusion kit 2 used; brain tissue distribution; post op. care (buprenophine).

P7169 Garcia-Castro,J., Martinez-Palacio,J., Lillo,R., Garcia-Sanchez,F., Alemany,R., Madero,L., Bueren,J.A., Ramirez,M. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Therapy 2005; 12(-4-):341-349. >>> Fluorocytosine, 5-; SC; Mice (SCID); 2004; 4 weeks; Cancer (breast, prostate).

P7166 Cool,J.C., Dyer,J.L., Xian,C.J., Butler,R.N., Geier,M.S., Howarth,G.S. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. GROWTH HORMONE&IGF RESEARCH 2005; 15(-1-):72-82. >>> Insulin-like growth factor I, recomb.human; Acetic acid; SC; Rat; 2002; 7 days; Controls received mp w/ vehicle, no stress (see pg. 75), cancer, peptides, orally administered IGF-1 degrades rapidly in the gastric environment.

P7142 Ruan,W.F., Monaco,M.E., Kleinberg,D.L. Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology 2005; 146(-3-):1170-1178. >>> Insulin-like growth factor I, des(1-3); SC; Mice; 1007D; 1002; 5, 28 days; Controls received placebo; replacement therapy (IGF-I [-/-], oophorectomy); pumps replaced at day 14; cancer (breast); endocrinology.

P7136 Bandyopadhyay,A., Wang,L., Loepz-Casillas,F., Mendoza,V., Yeh,I.T., Sun,L.Z. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. PROSTATE 2005; 63(-1-):81-90. >>> Transforming growth factor-B3 receptor, recomb. soluble; PBS; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 84,88); cancer (prostate); multiple pumps per animal (2).

P7135 Benlloch,M., Ortega,A., Ferrer,P., Segarra,R., Obrador,E., Asensi,M., Carretero,J., Estrela,J.M. Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. Journal of Biological Chemistry 2005; 280(-8-):6950-6959. >>> Acivicin; verapamil; IV; Mice; 2001D; 7 hours; Controls received mp w/ physiological saline; cancer (melanoma).

P7125 Lynch,JJ III, Wade,C.L., Mikusa,J.P., Decker,M.W., Honore,P. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model. European Journal of Pharmacology 2005; 509(-1-):43-48. >>> Vincristine sulfate; Saline, physiological; IV (external jugular); Rat; 2002; 1-3 weeks; Cancer; mp primed overnight.

P7120 Khan,A., Jallo,G.I, Liu,Y.J, Carson,B.S., Guarnieri,M. Infusion rates and drug distribution in brain tumor models in rats. Journal of Neurosurgery (Pediatrics 1) 2005; 102(--):53-58. >>> Carboplatin; doxorubicin; transferrin-doxorubicin; CSF/CNS; Rat; 2ML1; 2001; 7 days; Cancer (glioma, gliosarcoma); brain tissue distribution; CNS infusion rate study; "...the use of intratumoral infusions significantly increase survival in comparison with bolus injections and conventional systemic treatments." P. 53; flexible tipped cannula components were from Plastics One; in some cases the tubing/cannula were left empty after implantation to allow the tissue to seal before fluid flow.

P7022 Shi,Y.Q., Wu,J.M., Mick,R., Cerniglia,G.J., Cohen-Jonathan,E., Rhim,J.S., Koch,C.J., Bernhard,E.J. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival. PROSTATE 2005; 62(-1-):69-82. >>> L-744832; L-788123; DMSO; water, sterile distilled; SC; Mice (nude); 1007D; 3,7 days; Controls received mp w/ vehicle; enzyme inhibitor (farnesyltransferase); cancer (prostate); 50% DMSO; tumor irridiated on day 3.

P6942 El-Salhy,M. Effects of triple therapy with octreotide, galanin and serotonin on a human colon cancer cell line. Oncology Reports 2005; 13(-1-):45-49. >>> Octreotide; galanin; serotonin; Saline; IP; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; cancer (colon).

P6928 El-Salhy,M. Effects of triple therapy with octreotide, galanin and serotonin on a human colon cancer cell line implanted in mice: comparison between different routes of administration. Histology and Histopathology 2005; 20(-1-):19-25. >>> Octreotide; galanin; serotonin; Saline; SC; IP; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. IP mp; cancer (colon); "continuous i.p infusion appears, however to be the most effective route of administration." (p. 19,25).

P6894 Tejeda,M, Gaal,D., Csuka,O., Keri,G.Y. Growth Inhibitory Effect of the Somatostatin Structural Derivative (TT-232) on Leukemia Models. Anticancer Research 2005; 25(--):325-330. >>> TT-232; Acetic acid; sodium acetate; water; mannitol; IV; SC; Mice; 2002; 14, 28 days; Dose-response (p. 328, fig 1); comparison of IP/SC injections vs. SC/IV mp; pumps replaced at day 14 for 28 day group; stability verified, 37 degrees Celsius for over 3 weeks; cancer (leukemia); TT-232 is a novel somatostatin analog; "The IV infusion for 28 days resulted in 82% growth inhibition." (p. 328); "The infusion of TT-232 by ALZET osmotic minipump resulted in 70-80% tumor growth inhibition and 20% tumor free survival." (p. 329); "…serial injections represent significant stress to the animals…" "To reduce and eliminate the above mentioned problem [stress] we used an ALZET osmotic minipump…" "Infusion from inserted ALZET minipumps maintains a constant drug level, resulting in a well defined, consistent pattern of drug exposure throughout the period of drug administration." "These studies suggest that TT-232 is a potent inhibitor of leukemia tumor in vitro and in vivo and suggest infusion treatment as a beneficial application in clinical practice." (p. 330); oligopeptide; enzyme inhibitor (tyrosine kinase); animal info (CBA/ca, immunosuppressed, female).

R0208 Shoji,Y., Nakashima,H. Current status of delivery systems to improve target efficacy of oligonucleotides. CURRENT PHARMACEUTICAL DESIGN 2004; 10(-7-):785-796. >>> Oligonucleotide, antisense; SC; intratumoral; ; Cancer (adenocarcinoma); surgical sutures used to immobilize the pumps.

P7139 de Lussanet,Q.G., Beets-Tan,R.G.H., Backes,W.H., van der Schaft,D.W.J., van Engelshoven,J.M.A., Mayo,K.H., Griffioen,A.W. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice. European Journal of Cancer 2004; 40(-8-):1262-1268. >>> Anginex; Saline; SC; Mice; 16 days; Controls received mp w/ vehicle; comparison of TNP-470 IP injections vs. mp; cancer (melanoma); MRI; mp removed at start of MRI procedure; pumps removed for MRI.

P7098 Kawakami,K., Kawakami,M., Puri,R.K. Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model. Clinical Cancer Research 2004; 10(-15-):5264-5270. >>> MLA; IP; Mice (nude); 1007D; 7 days; Cancer (head, neck); MLA is NW-monomethyl-L-arginine.

P7087 Andratschke,N.H., Nieder,C., Price,R.E., Rivera,B., Tucker,S.L., Ang,K.K. Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2004; 60(-4-):1257-1263. >>> Platelet-derived growth factor-BB; SC; CSF/CNS (cisterna magna, intrathecal); Rat; 2ML1; 4 days; Controls received mp w/ saline; functionality of mp cannulas and catheters verified before implantation and after removal; dose-response (table 2); no stress (see pg. 1261); cancer; toxicology.

P7081 Matsuno,A., Katayama,H., Murakami,M., Nagashima,T. In vivo growth suppression of rat C6 glioma transplanted in rat brain using antisense oligonucleotide for microtubule-associated protein 1A messenger ribonucleic acid. British Journal of Neurosurgery 2004; 18(-4-):343-346. >>> Oligodeoxynucleotide, phosphorothisate antisense; oligodeoxynucleotide, phosphorothisate sense; oligodeoxynucleotide, phosphorothisate scramble; Saline, sterile; CSF/CNS (intratumoral); Rat; 1007D; 1 week; Controls received mp w/ sense or scrambled oligos; antisense (microtubule-associated protein 1A); cancer (glioma).

P7077 Lefranc,F., Mijatovic,T., Mathieu,V., Rorive,S., Decaestecker,C., Debeir,O., Brotchi,J., Van Ham,P., Salmon,I., Kiss,R. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. Clinical Cancer Research 2004; 10(-24-):8250-8265. >>> Gastrin-17; Saline; CSF/CNS (intratumoral); Rat (nude); 1002; 7 days; Controls received mp w/ vehicle; stability verified; cancer (glioma).

P7075 Thijssen,V.L.J.L., Brandwijk,R.J.M.G., Dings,R.P.M., Griffioen,A.W. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Experimental Cell Research 2004; 299(-2-):286-293. >>> Anginex; Saline; SC; Mice (nude); 2004; 20 days; Controls received mp w/ vehicle; cancer (melanoma, ovarian carcinoma).

P7073 Thallinger,C., Wolschek,M.F., Maierhofer,H., Skvara,H., Pehamberger,H., Monia,B.P., Jansen,B., Wacheck,V., Selzer,E. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of Mcl-1 antisense Oligonucleotides with low-dose cyclophosphamide. Clinical Cancer Research 2004; 10(-12-):4185-4191. >>> Oligodeoxynucleotide, phosphorothisate antisense; oligonucleotide, universal control; Saline; SC; Mice (SCID); 2002; 2 weeks; Controls received mp w/ vehicle, or UC oligo; antisense (Mcl-1); cancer (liposarcoma).

P7070 Foster,HE Jr, Yono,M., Shin,D., Takahashi,W., Pouresmail,M., Afiatpour,P., Latifpour,J. Effects of chronic administration of doxazosin on alpha1-adrenoceptors in the rat prostate. Journal of Urology 2004; 172(-6-):2465-2470. >>> Doxazosin; DMSO; SC; Rat; 8,12 weeks; Controls received mp w/ vehicle; dose-response (table 2); long-term study; cancer (prostatic hyperplasia); 50% DMSO; due to limitations in solubility mp was combined with oral dosing to deliver higher doses.

P7066 Lynch,JJ III, Wade,C.L., Zhong,C.M.M., Mikusa,J.P., Honore,P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 2004; 110(-1-2-):56-63. >>> Vincristine sulfate; Saline, physiological; IV (jugular); Rat; 2002; 14 days; Controls received mp w/ vehicle; no stress (see pg. 58); cancer; mp primed overnight.

P7065 Masunaga,S.I., Takahashi,A., Ohnishi,K., Ohnishi,T., Nagata,K., Suzuki,M., Kinashi,Y., Ono,K. Effects of mild temperature hyperthermia and p53 status on the size of hypoxic fractions in solid tumors, with reference to the effect in intratumor quiescent cell populations. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2004; 60(-2-):570-577. >>> Uridine, bromodeoxy-; Saline, physiological; SC; Mice (nude); 2001; 7 days; Controls received no treatment; cancer (squamous cell carcinoma).

P7054 Matthey,B., Borchmann,P., Schnell,R., Tawadros,S., Lange,H., Huhn,M., Klimka,A., Tur,M.K., Barth,S., Engert,A., Hansen,H.P. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. International Journal of Cancer 2004; 111(-4-):568-574. >>> BB-3644; PBS; SC; Mice (SCID); 2001; 8 days; Controls received mp w/ vehicle; comparison of IV injections vs. mp; enzyme inhibitor (metalloproteinases); cancer (lymphoma); "when BB-3644 was continuously applied via a small osmotic pump, the antitumor activity of a single dose of Ki-3(scFv)-ETA' was further enchanced with a tumor-free survival of all animals treated for more than 200 days." (p. 572).

P7052 Alley,M.C., Hollingshead,M.G., Pacula-Cox,C.M., Wand,W.R., Hartley,J.A., Howard,P.W., Gregson,S.J., Thurston,D.E., Sausville,E.A. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations. Cancer Research 2004; 64(-18-):6700-6706. >>> SJG-136; DMSO; PEG; IV (jugular); Mice (nude); 2001; 5 days; Controls received mp w/ vehicle; comparison of IV injections vs. mp; no stress (see pg. 6706); cancer (melanoma); agent also known as NSC 694501; 50% DMSO; "It is noteworthy that 5-day continuous infusions are highly effective in the LOX IMVI tumor model...continuous infusions were highly active and the lower peak plasma concentrations afforded by them may render infusion a useful mode for SJG-136 delivery in man." (pg. 6704-5).

P7028 Harrington,K.J., Syrigos,K.N., Uster,P.S., Zetter,A., Lewanski,C.R., Gullick,W.J., Vile,R.G., Stewart,J.S.W. Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model. British Journal of Cancer 2004; 91(-2-):366-373. >>> Uridine, iododeoxy-; DMSO; water distilled; SC; Mice (nude); 2002; 7 days; Controls received PBS injections; comparison of pegylated liposomes vs. IV bolus injections vs. mp; no stress (pg. 370); cancer (head and neck); toxicology; 20% DMSO; therapeutic irradiation with 137Cs source after day 7.

P7005 Duncan,R.E., El-Sohemy,A., Archer,M.C. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. Journal of Biological Chemistry 2004; 279(-32-):33079-33084. >>> Mevalonate; SC; Mice (nude); 2004; 13 weeks; Controls received mp w/ vehicle, or isotonic saline; long-term study; pumps replaced every 28 days; cancer (MDA-MB-435); MDA-MB-435 is a highly malignant human cancer of either breast adenocarcinoma or occult melanoma (origin uncertain); cancer (breast, melanoma, adenocarcinoma).

P6992 Wolfe,D., Niranjan,A., Trichel,A., Wiley,C., Ozuer,A., Kanal,E., Kondziolka,D., Krisky,D., Goss,J., DeLuca,N., Murphey-Corb,M., Glorioso,J.C. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Therapy 2004; 11(-23-):1675-1684. >>> Ganciclovir; SC; Monkey (Rhesus); 2ML1; 2ML2; 4,5,34,35 days; Pumps replaced after 2 weeks; no stress (see pg. 1677); cancer (glioblastoma); toxicology; MRI; multiple pumps per animal (2); gene therapy.

P6923 Kawakami,K., Kawakami,M., Kioi,M., Husain,S.R., Puri,R.K. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. Journal of Neurosurgery 2004; 101(-6-):1004-1011. >>> Interleukin-13, PE38; Albumin, human serum; PBS; CSF/CNS; Mice (nude); 1007D; 7 days; Comparison of CNS injections vs. mp; cancer (glioma); ALZET brain infusion kit; cyanoacrylate adhesive.

P6839 Thordarson,G., Slusher,N., Leong,H., Ochoa,D., Rajkumar,L., Guzman,R., Nandi,S., Talamantes,F. Insulin-like growth factor (IGF)-I obliterates the pregnancy-associated protection against mammary carcinogenesis in rats: evidence that IGF-I enhances cancer progression through estrogen receptor-alpha activation via the mitogen-activated protein kinase pathway. BREAST CANCER RESEARCH 2004; 6(-4-):R423-R436. >>> Insulin-like growth factor I, recomb. human; SC; Rat (pregnant); 60 days; Controls received mp w/ vehicle or no treatment; functionality of mp verified by IGF-I plasma levels; cancer (mammary).

P6838 Thordarson,G., Semaan,S., Low,C., Ochoa,D., Leong,H., Rajkumar,L., Guzman,R.C., Nandi,S., Talamantes,F. Mammary tumorigenesis in growth hormone deficient spontaneous dwarf rats; effects of hormonal treatments. Breast Cancer Research and Treatment 2004; 87(-3-):277-290. >>> Insulin-like growth factor I, recomb. human; SC; Rat; 21 weeks; 10 days; Controls received no treatment; replacement therapy (GH deficient, dwarf); long-term study; cancer (mammary); peptides.

P6815 Wang,J., Zheng,H., Ou,X., Albertson,C.M., Fink,L.M., Herbert,J.M., Hauer-Jensen,M. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2004; 2(-11-):2027-2035. >>> Hirudin; Saline; IP; Rat; 2ML2; 16 days; Controls received mp w/ vehicle; enzyme inhibitor thrombin; cancer (abdominal, pelvic); toxicology; scrotal hernia created via orchiectomy w/ a loop of ileum sutured to inside of scrotum.

P6814 Wang,Q.C., Horiatis,D., Pinski,J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. International Journal of Cancer 2004; 111(-4-):508-513. >>> Interleukin-6; SC; Mice (nude); 3 weeks; Controls received SC saline injections; comparison of SC injections vs. mp; no stress (see pg. 511); cancer (prostate).

P6812 Yang,Z.J., Sun,X.H., Li,S.K., Tan,Y.Y., Wang,X., Zhang,N., Yagi,S., Takakura,T., Kobayashi,Y., Takimoto,A., Yoshioka,T., Suginaka,A., Frenkel,E.P., Hoffman,R.M. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate. Cancer Research 2004; 64(-16-):5775-5778. >>> Pyridoxal-5'-phosphate; Water, distilled; sodium hydroxide; SC; Mice; 2001; 5 days; Controls received mp w/ vehicle; functionalityof mp verified by plasma PLP levels; dose-response (fig. 1); cancer.

P6799 Iimuro,S., Shindo,T., Moriyama,N., Amaki,T., Niu,P., Takeda,N., Iwata,H., Zhang,Y.L., Ebihara,A., Nagai,R. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circulation Research 2004; 95(-4-):415-423. >>> Adrenomedullin; AM22-52; suramin; Saline; SC; Mice; 2002; ; Controls received mp w/ PBS; cancer (murine sarcoma); cardiovascular; peptides; AM22-52 is an adrenomedullin antagonist; ischemia (cardiac).

P6796 Xian,C.J., Howarth,G.S., Cool,J.C., Foster,B.K. Effects of acute 5-fluorouracil chemotherapy and insulin-like growth factor-I pretreatment on growth plate cartilage and metaphyseal bone in rats. Bone 2004; 35(-3-):739-749. >>> Insulin-like growth factor I, recomb. human; Acetic acid; SC; Rat; 7 days; Controls received mp w/ vehicle; cancer; osteoporosis.

P6791 Olsson,A.K., Johansson,I., Aakerud,H., Einarsson,B., Christofferson,R., Sasaki,T., Timpl,R., Claesson-Welsh,L. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Research 2004; 64(-24-):9012-9017. >>> Endostatin (180-199), human; endostatin (180-199/mut), human; IP; Mice (SCID); 1007D; 3 weeks; Controls received mp w/ endostatin (180-199/mut); comparison of SC injections vs. mp; pumps replaced every week; cancer (pancreatic carcinoma); peptides; "Continuous delivery of endostatin w/ mini osmotic pumps implanted intraperitoneally in mice has been shown to be more efficient and to require a lower dose to achieve the same antitumor effect." (p. 9015).

P6790 Seo,Y., Yan,T., Schupp,J.E., Colussi,V., Taylor,K.L., Kinsella,T.J. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2-deoxyribose. Clinical Cancer Research 2004; 10(-22-):7520-7528. >>> Uridine, iododeoxy; NaOH; SC; Mice (nude); 2001; 7 days; Comparison of oral IPdR vs. mp; cancer (colon); athymic; "the use of oral IPdR results in dramatically higher but transient plasma IUdR levels in comparison with continuous infusion IUdR." (p. 7523).

P6775 Gawlick,U., Kranz,D.M., Schepkin,V.D., Roy,E.J. A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors. Bioconjugate Chemistry 2004; 15(-5-):1137-1145. >>> Antibody, anti-CD28 Fab/Folate; gadolinium; PBS; CSF/CNS (intratumoral); Mice (transgenic); 1002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by MRI w/ gadolinium infusion; comparison of IV, SC, ICV injections vs. mp; cancer (brain, choroid plexus); brain tissue distribution; MRI; cyanoacrylate adhesive; "The strongest effect on tumor growth assessed of anti-CD28 fab/Folate." (p. 1143). Plastics One cannula used.

P6774 Bello,L., Lucini,V., Costa,F., Pluderi,M., Giussani,C., Acerbi,F., Carrabba,G., Pannacci,M., Caronzolo,D., Grosso,S., Shinkaruk,S., Colleoni,F., Canron,X., Tomei,G., Deleris,G., Bikfalvi,A. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clinical Cancer Research 2004; 10(-13-):4527-4537. >>> PEX, recomb. human; PF-4/CTF; P4-4/DLR; vascular endothelial growth inhibitor, cyclo-; Water, sterile; SC; Mice; mice (nude); 2004; 28, 112, 140 days; Dose-response; long-term study; pumps replaced every 28 days; no stress (see pg. 4532); cancer (glioma); peptides; "The treatment was always very well tolerated without the occurrence of any side effects." (p. 4532); angiogenesis inhibitor.

P6771 Takenaga,M., Tamamura,H., Hiramatsu,K., Nakamura,N., Yamaguchi,Y., Kitagawa,A., Kawai,S., Nakashima,H., Fujii,N., Igarashi,R. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochemical and Biophysical Research Communications 2004; 320(-1-):226-232. >>> TE14011, 4F-benzoyl-; Saline; SC; Mice; 1002; 2 weeks; Controls received microcapsules w/ vehicle; comparison of microcapsules vs. SC injections vs. mp; cancer (pulmonary); peptides; CXCR4 antagonist; "These results also show that a sustained drug release formulation could be useful drug delivery system for CXCR4 antagonists." (abstract).

P6765 Neal,Z.C., Yang,J.C., Rakhmilevich,A.L., Buhtoiarov,I.N., Lum,H.E., Imboden,M., Hank,J.A., Lode,H.N., Reisfeld,R.A., Gillies,S.D., Sondel,P.M. Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clinical Cancer Research 2004; 10(-14-):4839-4847. >>> Interleukin-2, recomb. human; SC; Mice; 2001; 7 days; Controls received mp w/ PBS; no stress (see pg.4841); cancer (neuroblastoma); peptides.

P6764 Frewert,S., Stockhammer,F., Warschewske,G., Zenclussen,A.C., Rupprecht,S., Volk,H.D., Woiciechowsky,C. Intratumoral infusion of interleukin-1 beta and interferon-gamma; induces tumor invasion with macrophages and lymphocytes in a rat glioma model. Neuroscience Letters 2004; 364(-3-):145-148. >>> Interleukin-1, beta recomb. rat; Interferon-gamma, recomb. rat; Saline, physiological; albumin, human serum; CSF/CNS (intratumoral); Rat; 1003D; 48 hours; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioma).

P6745 Gourdeau,H., Leblond,L., Hamelin,B., Dong,K., Ouellet,F., Boudreau,C., Custeau,D., Richard,A., Gilbert,M.J., Jolivet,J. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: Implications for clinical development. Clinical Cancer Research 2004; 10(-22-):7692-7702. >>> Troxacitabine; Saline; SC; Mice; 2001; 1,3,5,6 days; Controls received mp w/ vehicle; functionality of mp verified by plasma concentrations; dose-response (fig 3); comparison of IV injections vs. mp; cancer (colon); toxicology; agent also known as Troxatyl BCH-4556; Athymic.

P6725 Shannon,K.E., Keene,J.L., Settle,S.L., Duffin,T.D., Nickols,M.A., Westlin,M., Schroeter,S., Ruminski,P.G., Griggs,D.W. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. CLINICAL&EXPERIMENTAL METASTASIS 2004; 21(-2-):129-138. >>> S247; SC; Mice (SCID); 2,4,8 weeks; Controls received mp w/ vehicle; half-life (p. 133), 5 hours; cancer (lung); S247 is a RGD peptidomimetic compound.

P6720 Gondi,C.S., Lakka,S.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,J.S., Rao,J.S. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. ONCOGENE 2004; 23(--):8486-8496. >>> RNA, small interfering; EV/SV vector; PBS; CSF/CNS (intratumoral); Mice (nude); ; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioma); gene therapy; antiangiogenesis; siRNA (cathepsin B); pump model not stated (0.25 ul/hr); "...local intracranial delivery of pcu using mini-osmotic pumps effectively inhibited human malignant glioma growth.".

P6646 Aharinejad,S., Paulus,P., Sioud,M., Hofmann,M., Zins,K., Schaefer,R., Stanley,E.R., Abraham,D., Aharinejad,S. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Research 2004; 64(--):5378-5384. >>> Oligonucleotide, antisense; oligonucleotide, scrambled; Ringer's solution; SC; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; antisense (CSF)-1; cancer (carcinoma, breast); transplantation.

P6633 Tsutsumi,N., Yonemitsu,Y., Shikada,Y., Onimaru,M., Tanii,M., Okano,S., Kaneko,K., Hasegawa,M., Hashizume,M., Maehara,Y., Sueishi,K. Essential role of PDGFR alpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo - Role of PDGFR alpha during angiogenesis. Circulation Research 2004; 94(-9-):1186-1194. >>> Antibody, polyclonal anti-PDGF-AA; IP; Mice; 1007D; 2001; 7 days; Cancer; cardiovascular.

P6618 Lakka,S.S., Gondi,C.S., Yanamandra,N., Olivero,W.C., Dinh,D.H., Gujrati,M., Rao,J.S. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. ONCOGENE 2004; 23(-27-):4681-4689. >>> RNA, small interfering; human cytomegalovirus promoter; Empty vector; CSF/CNS; Mice; 2004; 5 weeks; Cancer (glioblastoma); siRNA against mmp-9 and cathepsin; antiangiogenesis; gene therapy.

P6565 Morita,T., Shibata,K., Kikkawa,F., Kajiyama,H., Ino,K., Mizutani,S. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. International Journal of Cancer 2004; 109(-4-):525-532. >>> Oxytocin; IP; Mice (nude); 2002; 2 weeks; Controls received w/ physiological saline; no stress (see pg.530); cancer (ovarian carcinoma).

P6557 Chi,K.H., Wang,H.E., Wang,Y.S., Chou,S.L., Yu,H.M., Tseng,Y.H., Hwang,I.M., Lui,W.Y. Antisense thymidylate synthase electrogene transfer to increase uptake of radiolabeled iododeoxyuridine in a murine model. Journal of Nuclear Medicine 2004; 45(-3-):478-484. >>> Uridine; iodoeoxy; radio-isotopes; Saline, normal; 131I tracer; Intratumoral; Mice; 2001; 7 days; Controls received mp w/ PBS; cancer; "The present study was designed to increase the extent of cellular uptake of 131I-IdUrd in experimental tumors by using a miniosmotic pump." (p. 483).

P6554 Hjortland,G.O., Garman-Vik,S.S., Juell,S., Olsen,O.E., Hirschberg,H., Fodstad,O., Engebraaten,O. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. Journal of Neurosurgery 2004; 100(-2-):320-327. >>> Antibody, monoclonal 9.2.27 - pseudomonas exotoxin A; dye, evans blue; PBS; CSF/CNS (intratumoral); Rat (nude); 2001D; 24 hours; Controls received mp w/ PBS; cancer (glioma biopsy tumors); ALZET brain infusion kit used; brain tissue distribution; mp primed in sterile saline at 37 degrees Celsius for 4 hours; mp removed after 3 days.

P6547 Aparicio,T., Guilmeau,S., Goiot,H., Tsocas,A., Laigneau,J.P., Bado,A., Sobhani,I., Lehy,T. Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. Gastroenterology 2004; 126(-2-):499-510. >>> Leptin, recomb. mouse; Saline; BSA; SC; IP; Intraluminal (colon); Rat; 2ML1; 7,23 days; Controls received mp w/ vehicle; functionality of mp verified by plasma concentrations; comparison of 2 daily colonic lumen injections vs. mp; pumps replaced every 8 days to ensure peptide activity; cancer (colon); peptides.

P6537 McLaughlin,P.J., Stack,BC Jr, Braine,K.M., Ruda,J.D., Zagon,I.S. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: Dependency on the route of administration. INTERNATIONAL JOURNAL OF ONCOLOGY 2004; 24(-1-):227-232. >>> Enkephalin; Saline; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; OGF plasma levels taken; comparison of IP and intratumoral injections vs. SC mp; adverse reaction: (see pg. 229) "within 2 days...3 minipumps containing saline were spotaneously dislodged." [possible pocket too small]; cancer (carcinoma); peptides; enkephalin was met-5 and termed OGF or opioid growth factor.

P6535 Fischer,W., Gustafsson,L., Mossberg,A.K., Gronli,J., Mork,S., Bjerkvig,R., Svanborg,C. Human alpha-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Research 2004; 64(-6-):2105-2112. >>> Lactalbumin, alpha; HAMLET; radio-isotopes; 125I tracer; saline; CSF/CNS (intratumoral); Rat (nude); 2001D; 1 day; Tissue perfusion (tumor); functionality of mp verified by autoradiography on brain sections; no stress (see pg. 2108); cancer (glioblastoma); brain tissue distribution; agent is called HAMLET or (human alpha lact albumin made lethal to tumor cells); "...there were no signs of edema or tissue damage in the surrounding brain, including the cortex, which had been penetrated by the [26 gauge] infusion cannula." p. 2108.

P6534 Hu,D.E., Dyke,S.O.M., Moore,A.M., Thomsen,L.L., Brindle,K.M. Tumor cell-derived nitric oxide is involved in the immune-rejection of an immunogenic murine lymphoma. Cancer Research 2004; 64(-1-):152-161. >>> 1400W; PBS; SC; Mice; 2001; ; Controls received mp w/ vehicle; enzyme inhibitor (iNOS); cancer (lymphoma).

P6498 Nakamura,E.S., Koizumi,K., Kobayashi,M., Saiki,I. Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. CANCER SCIENCE 2004; 95(-1-):25-31. >>> MMI270; DMSO; PEG 300; IP; Mice; 2004; 15 days; Controls received mp w/ vehicle; no stress (see pg.27); enzyme inhibitor (matrix metalloproteinase); cancer (lung); MMI270 was formerly termed CGS27023A; 50% DMSO "The continuous administration of MMI270 for 15 days using an osmotic pump led to a significant decrease in the weight of tumor-metastasized lymph nodes" (p. 29).

P6482 Mellert,W., Kaufmann,W., Rossbacher,R., van Ravenzwaay,B. Investigations on cell proliferation in B6C3F1 mouse liver by diethanolamine. Food and Chemical Toxicology 2004; 42(-1-):127-134. >>> Uridine, 5-bromo-2'deoxy-; Saline; SC; Mice; 2001; 7 days; Cancer (liver); toxicology.

P6477 Browne,S.E., Roberts,LJ II, Dennery,P.A., Doctrow,S.R., Beal,M.F., Barlow,C., Levine,R.L. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radical Biology and Medicine 2004; 36(-7-):938-942. >>> EUK-189; Mannitol; SC; Mice; 2004; 56, 84 days; Controls received mp w/ vehicle; long-term study; pumps replaced every 28 days; no stress (see pg.941); cancer (thymoma); EUK-189 is a synthetic catalytic antioxidant w/ both catalase&superoxide dismutase activities; neurodegenerative (ataxia telangiectasia).

P6450 Jean,W.C., Spellman,S.R., Wallenfriedman,M.A., Flores,C.T., Kurtz,B.P., Hall,W.A., Low,W.C. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat. Journal of Neuro-oncology 2004; 66(-1-2-):39-49. >>> Colony-stimulating factor, GM; interleukin-2; interleukin-12; SC; Rat; 2004; 4 weeks; Cancer (gliosarcoma); GM-CSF was infused alone or with cytokines.

P6426 Harms,J.F., Welch,D.R., Samant,R.S., Shevde,L.A., Miele,M.E., Babu,G.R., Goldberg,S.F., Gilman,V.R., Sosnowski,D.M., Campo,D.A., Gay,C.V., Budgeon,L.R., Mercer,R., Jewell,J., Mastro,A.M., Donahue,H.J., Erin,N., Debies,M.T., Meehan,W.J., Jones,A.L., Mbalaviele,G., Nickols,A., Christensen,N.D., Melly,R., Beck,L.N., Kent,J., Rader,R.K., Kotyk,J.J., Pagel,M.D., Westlin,W.F., Griggs,D.W. A small molecule antagonist of the alpha v beta 3 integrin suppresses MDA-MB-435 skeletal metastasis. CLINICAL&EXPERIMENTAL METASTASIS 2004; 21(-2-):119-128. >>> S247; PBS; SC; Mice; 2002; 2004; 28 days; Controls received mp w/ vehicle; dose-response (p. 124,125); cancer (breast).

P6394 Sudoh,M., Kishimoto,Y., Marumoto,B., Inoue,M., Sano,A., Miura,N., Horie,Y., Hasegawa,J., Ryoke,K. A new animal model of continuous catheterization for investigating mechanisms of arteritis associated with chemotherapy. LIFE SCIENCES 2004; 74(-24-):3025-3032. >>> Fluorouracil, 5-FU; peplomycin; Saline, heparinized; IA (abdominal aorta); Rat; 2ML1; 7 days; Controls received mp w/ vehicle; cancer; chemotherapeutic agents; PE-10 and 60 used; tubing attached using a moment binding agent (alon-alfa); catheter schematic p. 3027; pump placed IP.

P6374 Souweidane,M.M., Occhiogrosso,G., Mark,E.B., Edgar,M.A., Dunkel,I.J. Interstitial infusion of carmustine in the rat brain stem with systemic administration of O(6)-benzylguanine. Journal of Neuro-oncology 2004; 67(-3-):319-326. >>> Carmustine; Dextrose water; CSF/CNS (brain stem); Rat; 2001D; 24 hours; Tissue perfusion (brain stem); good methods p. 321; cancer; carmustine (BCNU) was dissolved in 5% dextrose water; pump incorrectly listed as a 2001 model; 30 g Plastics One cannula used with vinyl tubing by DURECT.

P6373 Souweidane,M.M., Occhiogrosso,G., Mark,E.B., Edgar,M.A. Interstitial infusion of IL13-PE38QQR in the rat brain stem. Journal of Neuro-oncology 2004; 67(-3-):287-293. >>> Interleukin-13,PE38QQR; Saline; serum albumin; CSF/CNS (brain stem); Rat; 2001D; 24 hours; Tissue perfusion (brain stem); stability verified (7 days at 37 degrees Celsius); good methods p. 288; cancer; cyanoacrylate adhesive; pump incorrectly labeled as a 2001; IL13-PE38QQR is a tumor specific, chimeric cytotoxin; 30 g Plastics One Cannula used; vinyl catheter tubing from DURECT used.

P6352 Akhtar,N., Padilla,M.L., Dickerson,E.B., Steinberg,H., Breen,M., Auerbach,R., Helfand,S.C. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. NEOPLASIA 2004; 6(-2-):106-116. >>> Interleukin-12; PBS; SC; Mice (SCID); 2004; 1 week; Controls received mp w/ vehicle; functionality of mp verified by pump explantation, examination and tumor reduction; cancer (Hemangiosarcoma); peptides; pump model not listed; tumor cells from a canine.

P6344 El-Salhy,M., Dennerqvist,V. Effects of triple therapy with octreotide, galanin and serotonin on liver metastasis of human colon cancer in xenografts. Oncology Reports 2004; 11(--):1177-1182. >>> Octreotide; galanin; serotonin; Saline; IP; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; no stress (pg. 1179); cancer (colon).

P6265 Tepel,J., Kruse,M.L., March,C., Fiedler,A., Kapischke,M., Ketterer,T., Sipos,B., Kremer,B., Kalthoff,H. Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: A novel adjuvant treatment strategy for pancreatic ductal carcinoma. Pancreas 2004; 28(-1-):1-12. >>> Oligodeoxynucleotide, antisense; SC; Mice (SCID); 14 days; Tissue perfusion (intratumoral); comparison of IP injections vs. sc mp; cancer (pancreatic ductal carcinoma); transplantation; 200 ul pump used.

P5950 Schmidt,N.O., Ziu,M., Carrabba,G., Giussani,C., Bello,L., Sun,Y.P., Schmidt,K., Albert,M., Black,P.M., Carroll,R.S. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clinical Cancer Research 2004; 10(-4-):1255-1262. >>> Endostatin, recomb. murine; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 21 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; comparison of SC injections vs. chronic ICV mp; no stress (see pg. 1261); cancer (glioma); ALZET brain infusion kit 1 used (per Dr. Carroll); MRI; "The direct infusion of therapeutic compounds into brain tumors can overcome some of the obstacles of drug delivery." p. 1255; BIK's removed prior to MRI; "no signs of intracranial bleeding due to the presence of the pumps or antiangiogenic treatment were observed..." (p. 1261); angiogenesis inhibitor; surgical glue used to affix cannula to the skull.

top of page